Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma

NCT03771859 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03771859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03771859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
January 16, 2019
Completion date
December 9, 2025
Enrollment
152 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma